Axsome Therapeutics Profit Margin

The latest profit margin for AXSM is -24.68% as of June 2026. That compares with -49.88% in the prior-year period — up 50.5% year over year. That is below the Healthcare sector average of 13.89%. Investors often review this figure alongside Axsome Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, AXSM's profit margin moved from -49.88% to -24.68% — a 50.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Axsome Therapeutics's valuation or profitability profile.

Against Healthcare companies, AXSM currently prints -24.68% for profit margin, while the sector average sits near 13.89%. That is roughly 277.6% below the sector mean. Large gaps often invite a closer look at Axsome Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Axsome Therapeutics converts resources into returns. At -24.68%, AXSM may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -49.88% in the prior-year period — up 50.5% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting AXSM's profit margin (-24.68%), review year-over-year change from -49.88%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.